Polymeric Materials in Cancer Immunotherapy: Advances, Challenges, and Future Directions
Polymer Science & Technology · 22.09.2026 · 2 (9) · 654-680
DOI: 10.1021/polymscitech.6c00026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Polymer Science & Technology, online erschienen am 09.06.2026. Verfasst von Cong Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, Jilin 130061, Chi…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jilin Province, National Key Research and Development Program of China, Jilin University.
Abstract (Originalsprache)
Despite revolutionary advances in tumor immunotherapy, its efficacy is often limited by antigen heterogeneity, immune exhaustion, and impaired immune cell infiltration caused by the immunosuppressive tumor microenvironment (TME). Polymer nanocarriers, leveraging their tunable physicochemical properties, modular architecture, and high design flexibility, offer an ideal platform to overcome these bottlenecks. They can not only protect immunotherapeutic agents (e.g., antigens, adjuvants, checkpoint inhibitors) and enable their targeted and controlled release but also enhance antigen presentation, reinvigorate effector immune cell functions, and reprogram the immunosuppressive network through spatiotemporally precise immune regulation. Furthermore, the versatility of polymer platforms empowers various cutting-edge therapeutic modalities, including cancer vaccines, adoptive cell therapies, and oncolytic viruses, demonstrating broad application potential. This review systematically explores the design principles and targeting strategies of polymer materials for tumor immunotherapy, their key roles in modulating anti-tumor immunity, and the core challenges in their clinical translation. Finally, this review envisions a new intelligent research paradigm driven by artificial intelligence (AI)-aided design and validated by clinically relevant systems such as humanized animal models to accelerate the development of next-generation polymer-based immunotherapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, Jilin 130061, China.
- National-Local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin 130062, China.
- International Center of Future Science, Jilin University, Changchun, Jilin 130015, China.
- State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, Jilin 130012, China.
ORCID-Profile: Wenbo Yao, Yuning Zhang, Tianmeng Sun
Förderung
- Natural Science Foundation of Jilin Province
- National Key Research and Development Program of China
- Jilin University
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Wang, C., Zhang, J., Li, J., Fan, K., Yin, S., Yang, Y. G., Yao, W., Zhang, Y., & Sun, T. (2026). Polymeric Materials in Cancer Immunotherapy: Advances, Challenges, and Future Directions. Polymer Science & Technology, 2(9), 654-680. https://doi.org/10.1021/polymscitech.6c00026
Vancouver
Wang C, Zhang J, Li J, Fan K, Yin S, Yang YG, et al. Polymeric Materials in Cancer Immunotherapy: Advances, Challenges, and Future Directions. Polymer Science & Technology. 2026;2(9):654-680. doi:10.1021/polymscitech.6c00026
BibTeX
@article{Wang2026,
author = {Wang, Cong and Zhang, Jichuan and Li, Jiayu and Fan, Kaiqi and Yin, Shiqi and Yang, Yong-Guang and Yao, Wenbo and Zhang, Yuning and Sun, Tianmeng},
title = {Polymeric Materials in Cancer Immunotherapy: Advances, Challenges, and Future Directions},
journal = {Polymer Science & Technology},
year = {2026},
volume = {2},
number = {9},
pages = {654--680},
doi = {10.1021/polymscitech.6c00026}
}
EUVIMED